Introduction
Gastric cancer (GC) is one of the most prevalent malignant neoplasms of digestive system, the third leading cause of cancer-related death worldwide. 1 Although remarkable progess has been achieved in diagnosis and therapy of GC in the past decade, prognosis for advanced GC patients remains poor. 2 Among many types of drugs applied to GC treatment, 5-fluorouracil (5-FU)-based chemotherapy is the mainstream therapeutic strategy. 3, 4 Nevertheless, chemoresistance frequently occurs during chemotherapy, which is a key barrier to the efficacy of GC treatment. 5 Therefore, sequentially elucidating the underlying mechanism and discovering new therapeutic targets are imperative for developing effective therapies for GC patients.
Enhancer of zeste homologue 2 (EZH2), a vital catalytic subunit of PRC2, is a histone methyltransferase that epigenetically represses gene expression by promoting histone H3 lysine 27 trimethylation (H3K27me3). 6, 7 EZH2 expression is aberrantly increased in cancers and closely related to the tumor progression, metastasis, and poor prognosis. [8] [9] [10] Although the oncogenic roles of EZH2 in cancers are extensively characterized, few studies have investigated the association of EZH2 with acquired drug resistance. Therefore, it is important to test whether inhibition of EZH2 will hold promise in the treatment of chemoresistant cancers.
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In this study, we aimed to investigate the expression pattern and functional role of EZH2 in GC 5-FU resistance as well as its underlying molecular mechanism. Our study found that the expression level of EZH2 was upregulated in GC tissues and cell lines, especially in 5-FU-resistant tissues and cells. Functionally, EZH2 knockdown sensitized 5-FU-resistant GC cells to 5-FU. Mechanically, silencing of EZH2 improved the sensitivity of GC cells to 5-FU through epigenetically suppressing FBXO32 expression. Our study revealed a novel EZH2/FBXO32 regulatory axis which could overcome 5-FU resistance in GC.
Materials and methods sample collection and cell culture
A total of 36 tumor tissues and matched adjacent normal tissues were collected from GC patients who underwent surgery at the Huaihe Hospital of Henan University from 2013 to 2017. All patients signed informed consents before this study. This study had acquired the approval from the ethics committee of the Huaihe Hospital of Henan University. The normalized RNA-seq data of stomach adenocarcinoma were downloaded from The Cancer Genome Atlas (TCGA) data portal website (https://cancergenome.nih.gov/).
Human fetal gastric epithelial cell line GES-1, human GC cell lines (AGS and SGC-7901), and their 5-FU-resistant cell lines (AGS/5-FU and SGC-7901/5-FU), and HEK293T cells were obtained from American Type Culture Collection (Manassas, VA, USA). All cells were cultured in Roswell Park Memorial Institute-1640 medium (Gibco BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco) at 37°C with 5% CO 2 .
cell transfection Empty pcDNA3.1 vector (Vector), pcDNA3.1-FBXO32 (FBXO32), siRNA against EZH2 (si-EZH2) or FBXO32 (si-FBXO32) and their negative control (si-con) were designed and synthesized by Genepharma (Shanghai, People's Republic of China). All cell transfections were performed using the Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol.
Quantitative real-time Pcr (qrT-Pcr)
Total RNA was isolated using Trizol reagent (Invitrogen) and then reverse transcribed into cDNA using PrimeScript RT Reagent Kit (TaKaRa, Tokyo, Japan). EZH2 and FBXO32 expression levels were detected by qRT-PCR with the primes as follows: EZH2 forward, 5′-TTGTT GGCGGAAGCGTGTAAAATC-3′, EZH2 reverse, 5′-TCC CTAGTCCCGCGCAATGAGC-3′; FBXO32 forward, 5′-CCGGCATATGATGGATGCCCTGCAACTAGC-3′, FBXO32 reverse, 5′-GCTGGTCGACCTATGCCACTTA AGGAGAAC-3′.
5-FU sensitivity assay
The cell viability of AGS/5-FU and SGC-7901/5-FU cells and their parental cells was measured by MTT assay. 5-FU sensitivity was determined using the half-maximal inhibitory concentration (IC50) value. The IC50 value was calculated using GraphPad Prism 7.0 software (GraphPad Software, La Jolla, CA, USA).
Flow cytometric analysis
Cell apoptosis was evaluated using Annexin V-FITC/ PI Apoptosis Detection Kit (KeyGEN Biotech, Nanjing, People's Republic of China) as described previously.
chromatin immunoprecipitation (chiP) assays
ChIP assay was performed to confirm the interaction between EZH2 and FBXO32 using the Magna ChIP™ A/G Chromatin Immunoprecipitation Kit (Millipore, Bellerica, MA, USA). Briefly, AGS/5-FU and SGC-7901/5-FU cells were lysed in a complete ChIP lysis buffer. Then, cell lysates were incubated with protein A/G magnetic beads and antibodies against EZH2 (Active Motif, Carlsbad, CA, USA), H3K27me3 (Millipore) or IgG (Millipore). Finally, qRT-PCR analysis was performed to determine the enrichment of FBXO32 in the immunoprecipitated DNA. The primers used were as follows: forward, 5′-GCAGCTATACGAGGTAGGACTGGGG-3′; reverse, 5′-TTGCAGTGAGCTGAGATCGCGC-3′.
Western blot analysis
Western blotting was performed according to our previously reported protocol. 12 The primary antibodies anti-FBXO32 and anti-GAPDH were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The antibody anti-EZH2 was purchased from BD Biosciences (San Jose, CA, USA).
lentivirus production and infection
shRNAs targeting the sequence of EZH2 or scrambled control were cloned into pLKO.1 vector (Addgene, Cambridge, MA, USA) to generate sh-EZH2 or sh-con lentivirus plasmids. sh-EZH2 or sh-con lentivirus plasmid was transfected into HEK293T cells together with ViraPower Lentiviral Packaging Mix (Thermo Fisher Scientific, Waltham, MA, USA). At 96 hours posttransfection, sh-EZH2 or sh-con virus supernatant was harvested to further infect AGS/5-FU 
Xenograft tumor model
The animal experiments were performed according to the national standard of the care and use of laboratory animals and got the approval of the Ethics Committee of Huaihe Hospital of Henan University. Approximately 1.0×10 7 AGS/5-FU cells stably infected with sh-EZH2 or sh-con were subcutaneously inoculated into the posterior flank of BALB/c-nude mice (4 weeks old) from the Shanghai Experimental Animal Center of the Chinese Academy of Sciences (Shanghai, People's Republic of China). One week later, mice were intraperitoneally injected with 6 mg/kg 5-FU or same volume of PBS every week according to indicated groups (n=5 each group): sh-con + PBS, sh-EZH2+ PBS, sh-con +5-FU, sh-EZH2+5-FU. The tumor sizes were measured with a digital caliper and volume was calculated using the following equation: volume = (length × width 2 /2). After 42 days, the mice were sacrificed, and the tumors were dissected out for weight assessment, qRT-PCR, and Western blot assay.
statistical analysis
All data were evaluated as means ± SD. Student's t-test and one-way analysis of variance were used to calculate the statistical difference using SPSS 16.0 software (SPSS, Inc., Chicago, IL, USA). Differences were considered statistically significant when P-value 0.05.
Results
eZh2 was upregulated in 5-FU-resistant gc tissues and cell lines
To investigate the role of EZH2 in GC, we first examined EZH2 expression in GC tissues from TCGA databases. The results indicated that EZH2 expression was significantly increased in GC tumor tissues compared with normal tissues ( Figure 1A ). To confirm the result, we further explored EZH2 expression in 36 paired GC tumor or adjacent normal tissues by qRT-PCR analysis. Consistently, EZH2 was significantly upregulated in GC tissues compared with adjacent normal tissues ( Figure 1B ). Additionally, compared with 5-FU-sensitive GC tissues, EZH2 expression was remarkably elevated in 5-FU-resistant GC tissues ( Figure 1C ). To further explore the expression of EZH2 in GC cells, Figure 3A) . Western blot analysis indicated that EZH2 knockdown significantly elevated FBXO32 expression in AGS/5-FU and SGC-7901/5-FU cells ( Figure 3B ; Figure S2A and B). To confirm that FBXO32 is transcriptionally repressed by EZH2 in our GC cells, we performed ChIP assays to evaluate the enrichment of EZH2 and the H3K27me3 on the FBXO32 promoter. The results revealed that EZH2 knockdown dramatically decreased EZH2 and H3K27me3 recruitment in the FBXO32 promoter in AGS/5-FU and SGC-7901/5-FU cells ( Figure 3C and D). All these data suggested that EZH2 epigenetically suppressed FBXO32 expression in GC cells. (Figure 1D and E) . Notably, AGS/5-FU and SGC-7901/5-FU cells exhibited higher EZH2 mRNA and protein levels than their parental cells ( Figure 1D and E) . Kaplan-Meier survival analysis revealed that patients with high EZH2 level had a low overall survival (P=0.0233) compared with that with low EZH2 level ( Figure 1F ). Taken together, these data demonstrated that upregulation of EZH2 may be implicated with 5-FU resistance in GC. 
FBXO32 overexpression enhanced 5-FU sensitivity of gc cells
eZh2 epigenetically suppressed FBXO32 expression in gc cells
Previous studies demonstrated that EZH2 could target FBXO32. 13 
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eZh2 knockdown enhanced 5-FU sensitivity in tumors in vivo
To further confirm the functional role of EZH2 in 5-FU resistance in vivo, AGS/5-FU cells infected with sh-con or sh-EZH2 were subcutaneously injected into the nude mice to generate a xenograft model, followed by treatment with 5-FU or PBS. The data revealed that EZH2 knockdown or 5-FU treatment significantly suppressed tumor growth, evidenced by the reduction in tumor volume ( Figure 6A ) and tumor weight ( Figure 6B ). Moreover, simultaneous EZH2 knockdown and 5-FU treatment resulted in a more distinct inhibition on tumor growth, suggesting downregulation of EZH2 facilitated the sensitivity of GC cells to 5-FU in vivo ( Figure 6A and B) . Additionally, qRT-PCR assay revealed that EZH2 mRNA levels were lowered, while FBXO32 expression was elevated in tumors after sh-EZH2 introduction or 5-FU treatment ( Figure 6C ), especially after combination of sh-EZH2 introduction and 5-FU treatment. Western blot assay revealed that EZH2 knockdown or 5-FU exposure greatly lowered EZH2 but improved FBXO32 protein levels in tumor tissues ( Figure 6D ). The combination of EZH2 knockdown and 5-FU exposure led to much reduced EZH2 and elevated FBXO32 protein expression ( Figure 6D ). All these data demonstrated that EZH2 depletion enhanced 5-FU sensitivity of GC cells in vivo.
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Discussion
Acquiring 5-FU resistance leads to limited therapeutic effectiveness for GC patients in the clinic at present. Hence, it is essential to investigate the molecular mechanism underlying 5-FU resistance and identify novel targets for 5-FU resistance prevention and therapy. In this study, we found that EZH2 expression was significantly increased in 5-FUresistant GC tissues and cells. Moreover, EZH2 knockdown sensitized AGS/5-FU and SGC-7901/5-FU cells to 5-FU by promoting cell apoptosis. More importantly, downregulation of EZH2 facilitated the sensitivity of GC cells to 5-FU via epigenetically suppressing FBXO32 expression. Therefore, EZH2 was confirmed to play a critical role in 5-FU resistance, providing a promising therapeutic target for 5-FU resistance in GC.
Elucidating the molecular mechanism underlying 5-FU resistance could contribute to developing reasonable and effective therapies to overcome 5-FU resistance. Our results demonstrated that EZH2 was upregulated in 5-FU-resistant GC tissues and cells, and EZH2 inhibition sensitized AGS/5-FU and SGC-7901/5-FU cells to 5-FU. Apart from our findings, several other studies have reported that abnormal EZH2 expression was implicated with 5-FU resistance in cancers. For example, EZH2 expression was elevated in hepatocellular carcinoma, and EZH2 depletion sensitized multidrug-resistant Bel/5-FU cells to 5-FU by suppressing MDR1 expression. 15, 16 Moreover, EZH2-mediated DPYD inhibition through regulating H3K27me3 at the DPYD promoter contributed to 5-FU resistance. 17 Prominently, miR-124-mediated inhibition submit your manuscript | www.dovepress.com
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Wang et al of EZH2 expression suppressed proliferation, induced apoptosis, and sensitized the treatment outcome of 5-FU in GC. 18 All these findings suggested that EZH2 inhibition could be used as a promising therapeutic strategy for 5-FU resistance in cancers.
The precise mechanism by which upregulated EZH2 expression confers 5-FU resistance is uncertain. Hence, the functional mechanism of EZH2 was further investigated in the present study. Previous studies demonstrated that EZH2 could target FBXO32. 13, 14 However, the interaction between EZH2 and FBXO32 in GC was still unclear. In the present study, ChIP assay verified that EZH2 directly inhibited FBXO32 expression in AGS/5-FU and SGC-7901/5-FU cells. FBXO32 (also known as atrogin-1) is a member of the F-box protein family and constitutes one of the four subunits of the ubiquitin protein ligase complex. 19, 20 Mounting evidence has revealed the emerging role of FBXO32 in tumorigenesis. 13, 21, 22 Moreover, FBXO32 was reported to be downregulated in ovarian cancer and GC, suggesting that FBXO32 may function as a tumor suppressor. 23, 24 Prominently, overexpression of FBXO32 induced apoptosis and enhanced chemosensitivity to cisplatin in ovarian cancer. 
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In conclusion, our study demonstrated that knockdown of EZH2 enhanced 5-FU sensitivity of GC cells. Importantly, the enhacing effect of downregulated EZH2 on 5-FU sensitivity might be mediated by FBXO32 in GC cells, providing a promising therapeutic strategy to overcome 5-FU resistance in GC. 
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